LifeArc®, the medical research charity, has appointed David Holbrook to manage its newly created Seed Fund. The £25m fund will invest in innovative early stage therapeutics and biological research aiming to deliver new treatments for patients.
Dave Tapolczay, CEO of LifeArc, said: “We are very pleased to have David onboard. The launch of our Philanthropic and Seed Funds this year is an exciting new way for LifeArc to shape the medical research landscape. David’s wide-ranging experience and expertise in life science investing will help us to back the projects with the most promise to make a difference for patients.”
David Holbrook, Head of Seed Funds at LifeArc, said: “I am delighted to be joining LifeArc at this exciting time in its evolution, and to be launching and managing a new player on the early stage investing scene. I look forward to harnessing LifeArc’s existing strengths and reach to help the fund deliver innovation to patients.”
The Seed Fund will be launched by mid-2018 and further details on the fund and its strategy will be disclosed nearer the time.
Copyright © 2023 Stevenage Bioscience Catalyst